News
TIL
7.17
+0.70%
0.05
Weekly Report: what happened at TIL last week (0914-0918)?
Weekly Report · 6d ago
Weekly Report: what happened at TIL last week (0907-0911)?
Weekly Report · 09/14 10:00
Weekly Report: what happened at TIL last week (0831-0904)?
Weekly Report · 09/07 09:55
Weekly Report: what happened at TIL last week (0824-0828)?
Weekly Report · 08/31 10:01
Weekly Report: what happened at TIL last week (0817-0821)?
Weekly Report · 08/24 10:01
Weekly Report: what happened at TIL last week (0810-0814)?
Weekly Report · 08/17 10:02
Instil Bio GAAP EPS of -$0.63 misses by $0.28
Seeking Alpha · 08/13 21:03
Instil Bio Q2 Adj. EPS $(0.45) Misses $(0.43) Estimate
Benzinga · 08/13 21:03
*Instil Bio 2Q Loss/Shr 63c >TIL
Dow Jones · 08/13 21:02
Weekly Report: what happened at TIL last week (0803-0807)?
Weekly Report · 08/10 09:58
Weekly Report: what happened at TIL last week (0727-0731)?
Weekly Report · 08/03 09:58
Weekly Report: what happened at TIL last week (0720-0724)?
Weekly Report · 07/27 10:01
Weekly Report: what happened at TIL last week (0713-0717)?
Weekly Report · 07/20 09:58
Weekly Report: what happened at TIL last week (0706-0710)?
Weekly Report · 07/13 10:00
Weekly Report: what happened at TIL last week (0629-0703)?
Weekly Report · 07/06 10:03
Weekly Report: what happened at TIL last week (0622-0626)?
Weekly Report · 06/29 09:59
Weekly Report: what happened at TIL last week (0615-0619)?
Weekly Report · 06/22 10:06
Weekly Report: what happened at TIL last week (0608-0612)?
Weekly Report · 06/15 10:07
Instil Bio Shareholders Back Directors and Auditor at Meeting
TipRanks · 06/11 22:18
Weekly Report: what happened at TIL last week (0601-0605)?
Weekly Report · 06/08 10:03
More
Webull provides a variety of real-time TIL stock news. You can receive the latest news about Instil Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TIL
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.